Capital Fund Management (CFM)’s SELLAS Life Sciences SLS Stock Holding History

Capital Fund Management (CFM)’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$277K	Buy	+18,747	New	+$129K	﹤0.01%	1991

Other funds holding SLS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Capital Fund Management (CFM)'s SLS Position: Q2 2026 in Review

Capital Fund Management (CFM) opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 18,747 shares worth $277K. The stake represents ﹤0.01% of the portfolio and ranks #1991 among its holdings.

192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

Capital Fund Management (CFM) held 18,747 shares of SELLAS Life Sciences worth $277K as of Q2 2026.
SELLAS Life Sciences was a new Capital Fund Management (CFM) position in Q2 2026.
SELLAS Life Sciences made up ﹤0.01% of Capital Fund Management (CFM)'s portfolio in Q2 2026, its #1991 holding.
192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Capital Fund Management (CFM)'s 13F filing for Q2 2026, filed 13 Aug 2026.